Annals of Oncology 12:1667-1670, 2001
© 2001 European Society for Medical Oncology
research-article |
Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
Institut Gustave Roussy Villejuif, France
T. Le Chevalier, MD, Department of Medicine, Institut Gustave Roussy, 39 rue Camille,Desmoulins 94805 Villejuif, France, E-mail: tle-che{at}igr.fr
Background: Platinum-based chemotherapy has been shown to be effective in improving survival and quality of life in advanced non-small-cell lung cancer (NSCLC) patients. The objective of this study was to identify patients more likely to benefit from chemotherapy in order to avoid the indiscriminate treatment of all patients.
Patients and methods: A multivariate analysis of survival was performed using the database of the European randomized phase III trial that compared vinorelbine (navelbine®) (NVB), vinorelbine-cisplatin (NVB-P) and vindesine-cisplatin (VDS-P) in 612 patients with inoperable NSCLC (stage III or IV). Interactions between treatment and the prognostic factors singled out by the Cox procedure were specifically tested.
Results: The performance status (PS) was the only significant interaction among the selected prognostic factors and treatment. Subgroup analysis showed that the advantage obtained with NVB-P predominantly concerned PS 0–1 patients, whose median survival lasted 43 weeks (95% confidence interval (95% CI): 39–50 weeks) with a one-year survival rate of 38% (95% CI: 31%–46%) versus 36 weeks (95% CI: 30–40 weeks) and 34% (95% CI: 27%–42%) for NVB alone, and 33 weeks (95% CI: 30–39 weeks) and 29% (95% Cl: 22%–36%) for VDS-P. In sharp contrast, survival in PS 2 patients was similar (median 18 weeks) (NVB-P 95% CI: 11–34 weeks; NVB 95% CI: 11–35 weeks; VDS-P 95% Cl: 14–32 weeks) whatever the treatment.
Conclusion: PS 2 patients with advanced NSCLC might not benefit from cisplatin combination therapy.
chemotherapy, multivariate analysis, non-small-cell lung cancer, performance status, prognostic factor
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. P. Sculier, J. J. Lafitte, M. Paesmans, J. Lecomte, C. G. Alexopoulos, O. Van Cutsem, V. Giner, A. Efremidis, M. C. Berchier, T. Collon, et al. Chemotherapy improves low performance status lung cancer patients Eur. Respir. J., December 1, 2007; 30(6): 1186 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S G Spiro, R M Rudd, R L Souhami, J Brown, D J Fairlamb, N H Gower, L Maslove, R Milroy, V Napp, M K B Parmar, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life Thorax, October 1, 2004; 59(10): 828 - 836. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Delbaldo, S. Michiels, N. Syz, J.-C. Soria, T. Le Chevalier, and J.-P. Pignon Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis JAMA, July 28, 2004; 292(4): 470 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gridelli, A. Ardizzoni, T. Le Chevalier, C. Manegold, F. Perrone, N. Thatcher, N. van Zandwijk, M. Di Maio, O. Martelli, and F. De Marinis Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel Ann. Onc., March 1, 2004; 15(3): 419 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli, C. Gallo, F. A. Shepherd, A. Illiano, F. Piantedosi, S. F. Robbiati, L. Manzione, S. Barbera, L. Frontini, E. Veltri, et al. Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., August 15, 2003; 21(16): 3025 - 3034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Cullen Lung cancer * 4: Chemotherapy for non-small cell lung cancer: the end of the beginning Thorax, April 1, 2003; 58(4): 352 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Malayeri Re: Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer J Natl Cancer Inst, August 7, 2002; 94(15): 1172 - 1172. [Full Text] [PDF]
|
|